microRNA-124在白血病及骨髓增生异常综合征患者中的表达异常及其意义

Abnormal Expression of MicroRNA-124 in Patients with Leukemia or Myelodysplastic Syndrome and Its Significance

本研究旨在探讨microRNA-124(miR-124)在白血病及骨髓增生异常综合征(MDS)骨髓细胞中的表达异常及其意义。采用茎环法实时荧光定量qRT-PCR技术检测10例正常骨髓组织、18例新确诊的白血病患者和15例MDS患者骨髓单个核细胞中miR-124的相对表达量;应用定量甲基化特异性聚合酶链反应检测部分MDS标本has-miR-124-1启动子甲基化水平。结果表明,部分白血病及MDS患者miR-124表达水平下调,其中下调至1/3以下的白血病患者比例为2/18,下调至1/3以下的MDS患者比例为5/15,下调至1/4以下的MDS患者比例为3/15。组间比较结果显示,miR-124在白血病组中的表达与正常骨髓相比差异无统计学显著意义(P=0.725),但在MDS标本中的表达水平降低有统计学显著意义(P=0.031);在7/11的MDS患者检测到miR-124启动子区甲基化水平升高,其中包括所有5例miR-124表达下调的患者。miR-124表达量与其启动子区域甲基化水平有相关性(R2=0.339,P=0.018)。结论:在部分MDS患者存在miR-124表达受抑,可能与其基因甲基化异常有关。

This study was aimed to investigate the abnormal expression of microRNA-124（miR-124） in bone marrow cells of patients with leukemia or myelodysplastic syndrome（MDS） and its significance.The relative expression levels of miR-124 in bone marrow mononuclear cells from 33 patients with newly diagnosed leukemia or MDS,and 10 normal donors（as controls） were detected by stem-loop fluorescence real-time quantitative RT-PCR.The methylation levels of miR-124 promoter were detected by quantitative mythylation specific PCR in partial MDS samples.The results indicated that as compared with normal control,lower levels of miR-124（≤1/3） were found in 2/18 of leukemia patients and in 5/15 of MDS patients（among them≤1/4 in 3/15 MDS patients）.No statistically significance difference was observed between leukemia patients and normal controls（P=0.725）.However the difference was statistically significant between MDS group and control group（P=0.031）.Furthermore,an elevated methylation level of miR-124 promoter region in some of MDS patients（7/11） was detected by using quantative methylation-specific PCR.The expression level of miR-124 was related with methylation level of promoter region（R2=0.339,P=0.018）.It is concluded that the expression of miR-124 in partial MDS patients is inhibited,which may be associated with the abnormal methylation of its promoter.